Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia

Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam
Department of Hematology, Guy's and St Thomas’ Hospit al, London
MAC Clinical Research, Manchester
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The OSU Wexner Medical Center, Columbus, OH
Department of Medicine, University of Minnesota, Minneapolis, MN
University College London Hospital, London
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
Medical University of South Carolina, Charleston, SC
CSL Behring, King of Prussia, PA
CSL Behring, King of Prussia, PA
CSL Innovation GmbH, Marburg
CSL Innovation, Victoria
CSL Behring, King of Prussia, PA
CSL Behring, King of Prussia, PA
CSL Behring, King of Prussia, PA
Department of Medicine, University of Illinois at Chicago, Chicago, IL
Haematologica Early view Mar 19, 2026 https://doi.org/10.3324/haematol.2025.300088

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2025.300088
 
Published
2026-03-19
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2026 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
86
PDF Downloads
28

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online